NEW YORK – Natera's personalized ctDNA assay technology has shown new potential as a tool to assess the efficacy of breast cancer neoadjuvant chemotherapy and potentially guide decisions regarding further adjuvant treatment after surgery.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
"breast" - Google News
December 05, 2020 at 03:30AM
https://ift.tt/3gfgf9k
Breast Cancer Trial Data Supports Neoadjuvant Use of Natera Liquid Biopsy - GenomeWeb
"breast" - Google News
https://ift.tt/2ImtPYC
https://ift.tt/2Wle22m
Bagikan Berita Ini
0 Response to "Breast Cancer Trial Data Supports Neoadjuvant Use of Natera Liquid Biopsy - GenomeWeb"
Post a Comment